OUR SERVICES

Pricing & Market Access

Expert pricing and market access support across the lifecycle.

WHY IT MATTERS

Canada's access pathway is interconnected rather than strictly sequential. Health Canada authorization, pricing and PMPRB obligations for patented medicines, HTA through CDA-AMC and INESSS, pCPA negotiations and individual payer listing decisions all need to be planned together. Some reimbursement reviews can begin before regulatory approval, and each jurisdiction ultimately makes its own funding decision. We build the evidence, pricing and negotiation strategy across those steps so the product enters each review with a clear and defensible value proposition.

CAPABILITIES

Pricing strategy & assessments

Launch pricing for patented medicines tested against PMPRB guidelines, international reference pricing and class comparators; list-versus-net modelling across channels

Market access readiness

Evidence and payer landscape assessment that surfaces gaps while they are still addressable

Reimbursement submissions

Dossier development and hands-on management through CDA-AMC for participating plans outside Quebec, INESSS in Quebec, and private payers, including reviews that begin before approval

Health economics & value evidence

Cost-effectiveness and budget impact models built to withstand committee re-analysis

Negotiations & payer contracting

pCPA negotiation, jurisdictional listing agreements and private payer strategy, pressure-tested through simulated negotiation before we engage

Payer & KOL advisory

Former payers and practising clinicians convened before submission, to test how the file will be received

Let's discuss your pricing and access plan

Book a call with our team